BioLife Solutions, LLC

🎙️ On Tuesday, November 10, in collaboration with Reg Med Net - the Regenerative Medicine Network, we’re leading a webinar on how controlling ice recrystallization can protect cryopreserved cell therapies from temperature-driven damage and preserve post-thaw quality and function.

🧊 You will hear from two cryobiology experts, Dr. Jason Acker and Dr. Robert Ben, who will share their experiences and promising evidence from working with small-molecule ice recrystallization inhibitors (IRIs).

If you’re looking to improve your cryopreservation processes and outcomes, please join us: https://www.regmednet.com/webinars/the-importance-of-ice-recrystallization-for-the-cryopreservation-of-cell-therapies/

We’re gearing up for the Advanced Therapies USA conference next week in Boston! ⚓

Save these activities to your calendar in the app:

✅ Stop by the BioLife booth 412 to chat with Andrew Sabatier, Amy Ma, Dr. Ana Clementin, and Vicky Tran. They can help you enhance process efficiencies, maintain cellular viability, and ensure reproducibility at every stage.

✅ Dr. Jason Acker is presenting a session on Wednesday, November 4, at 2:55pm called “Controlling Ice Recrystallization for Improved Cell Cryopreservation”.

✅ Check out two of our posters:

a. The Aby J. Mathew Center for Biopreservation Excellence compares serum-free media supplements in T cell generation processes.

b. The Panthera CryoSolutions team reports on preserving the post-thaw function of iPSC-derived iNK cells with ice recrystallization inhibitors.

👉 Reach out to us with any questions: https://biolifesolutions.com/contact/general-inquiries/

Will we see you in ONE week at the next ScaleReady and Emily Whitehead Foundation G-Rex Grant Tour Stop in Phoenix, AZ on November 4? 🌵

Make sure to connect with Rebecca Mercier and Sandy Jones at the BioLife table. We can’t wait to hear about the latest innovations in CAR-T therapy and listen to inspiring patient-advocate stories from Laurie Adami and Kim & Austin Schuetz.

If you haven’t made it to a tour stop yet, Phoenix and the December 9 Minneapolis, MN events are your last chance in 2026! 🚨

👉 Register now: https://www.scaleready.com/initiatives/g-rex-grant-tour-2026/g-rex-grant-tour-phoenix-az/

Early this summer, we hosted the second annual Cell Summit event at the Cincinnati Zoo in collaboration with Cincinnati Children's Hospital Medical Center.

We’re proud to announce that a proceedings eBook called “Designing the Ecosystem for CGT Success” from The Cell Summit ’26 has published through Genetic Engineering & Biotechnology News (GEN). 👏

☑️ This new eBook brings together perspectives from cell & gene therapy experts and leaders on key issues such as manufacturing scalability, supply chain logistics, CDMO partnerships, clinical delivery, reimbursement, and commercialization.

🤝 The eBook emphasizes that successful CGT adoption requires collaboration and coordination across the entire ecosystem, rather than improvements in individual processes alone. Overall, it highlights strategies and considerations for building an integrated, sustainable infrastructure that helps ensure these innovative therapies can reach patients effectively.

Download here: https://www.genengnews.com/resources/ebooks/designing-the-ecosystem-for-cgt-success/

How can developers better manage visible particulate risk in cell therapies?

Traditional particulate inspection and rejection criteria can present unique challenges for autologous and small batch therapies, where rejecting a single product unit could mean losing a life-saving treatment opportunity.

🔷 The ISCT, International Society for Cell & Gene Therapy - Process Development & Manufacturing Committee is proposing a new framework called the Visible Particulate Risk Assessment Matrix (VPRAM). Dr. Sean Werner, our Chief Technology Officer, is a contributor.

🔷 This new framework offers a risk-based approach to evaluating and managing particulates by integrating particle characteristics, manufacturing controls, administration considerations, clinical urgency, and the feasibility of replacing a rejected lot.

🔷 By balancing patient safety, product quality, and the distinctive clinical and manufacturing realities of cell therapies, VPRAM aims to support more informed and scientifically backed decision-making while still maintaining regulatory compliance.

Review the Cytotherapy article here🔎: https://www.isct-cytotherapy.org/article/S1465-3249(26)00890-X/fulltext

⚠️ Traditional cryobags can create real challenges for cell and gene therapy developers; from fractures and leaks to inspection challenges, complicated fill & finish workflows, storage limitations, and more.

We understand that changing established processes isn’t easy or quick. That’s why we developed the CellSeal® CryoCase - a rigid, cryogenic storage container designed specifically for CGTs, with improved inspectability, fracture resistance, and compatibility with closed-system processing.

🧠 Ready to rethink your cryostorage container approach?

We make the “case for CryoCase” in this slideshow:https://www.biolifesolutions.com/wp-content/uploads/2026/03/BioLifeSolutions_Cryobag_vs_CryoCase_Carousel_020626.pdf

Find out more and request samples: https://www.biolifesolutions.com/handling/cellseal-cryocase/

During routine handling, inventory management, testing and transportation, cryopreserved products can experience transient warming that promotes ice recrystallization, the growth of larger ice crystals at the expense of smaller ones. ❄️

This process can contribute to cellular damage and compromise post-thaw quality.

🎤 In an upcoming Reg Med Net - the Regenerative Medicine Network webinar on Tuesday, November 10, at 7am PT/10am ET/4pm CET, Dr. Jason Acker and Dr. Robert Ben will examine the science of ice formation and recrystallization, the impact of temperature excursions on cell stability, and emerging approaches to controlling ice-associated damage with ice recrystallization inhibitors (IRIs).

You will learn how IRIs:

☑️ Can strengthen cryopreservation processes
☑️ Work to limit ice crystal growth
☑️ Protect cells during transient warming events
☑️ Help preserve post-thaw cell quality, function, and more

👉 Register here:

The importance of ice recrystallization for the cryopreservation of cell therapies Experts will examine the science of ice formation and recrystallization, the impact of temperature excursions on cell stability, and emerging approaches to controlling ice-associated damage with ice recrystallization inhibitors

BioLife is exhibiting at Advanced Therapies USA in Boston from November 4-5, 2026 at the Hynes Convention Center. 🦞 ☕

Come to booth 412 to meet and greet with Andrew Sabatier, Amy Ma, Dr. Ana Clementin, and Vicky Tran. This is our last US trade show of 2026, and we’d like to hear about your successes and challenges from this year; and what you’d like to accomplish in 2027. 📝

We’re here to guide you to solutions that can enhance your process efficiency, maintain cellular viability, and ensure reproducibility at every stage.

🎤 Dr. Jason Acker is speaking on Wednesday, November 4, at 2:55pm on “Controlling Ice Recrystallization for Improved Cell Cryopreservation”. You don’t want to miss this talk on small-molecule ice recrystallization inhibitors and how they can enhance cell outcomes post-thaw.

Register soon if you haven’t yet: https://ow.ly/yf0h50ZTIEJ

How do you ensure better consistency, performance, and recovery in your cell culture reagents?

By starting with recombinant proteins that are high purity, animal origin-free, and have guaranteed bioactivity. ✅

📺 Watch our latest on-demand webinar hosted by Cell & Gene Therapy Review in collaboration with Dave Briner of BioLife Solutions, and Dr. Liz Stewart of Qkine. Dave and Liz shared important reagent considerations to maximize scale-up, reproducibility, quality documentation, and regulatory readiness in your organoid or cell and gene therapy processes.

Learn more: https://www.cellgenetherapyreview.com/3980-Webinars/627505-From-bench-to-batch-Building-reproducible-cell-and-gene-therapy-workflows-with-GMP-ready-reagents/?partnerref=biolifesolutions

We’re thrilled to announce that BioLife Solutions is now part of Repligen.

Repligen shares our commitment to providing innovative, differentiated, and enabling tools that help customers bring life-changing therapies to commercialization. Learn how our combined capabilities will support customers across the bioproduction workflow.

Press Release: https://www.globenewswire.com/news-release/2026/10/06/3375610/0/en/repligen-completes-acquisition-of-biolife-solutions.html